Inflammatory Bowel Diseases Clinical Trial
Official title:
A Single-centre, Randomized, Double-blind (Sponsor Unblinded), Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects
This study is the first administration of GSK2982772 in humans. The study will evaluate the
safety, tolerability, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) of single
and repeat oral doses of up to 14 days with GSK2982772 in healthy male subjects.
This study is planned to include approximately 52 subjects and will consist of 2 parts: Part
A - single ascending dose, randomized, placebo controlled, 4 way crossover. In addition to
the crossover treatment periods, up to 8 subjects in cohort 2 will participate in an
additional treatment period and receive GSK2982772 with a high-fat meal. Part B - repeat
dose, randomized, placebo controlled, sequential-group. In both cohorts of Part A (Cohorts 1
and 2), subjects will be randomized equally (1:1:1:1) to one of 4 treatment sequences.
Within each period, allocation of active to placebo treatment will be 3:1.
In all cohorts in Part B (Cohorts 3, 4 and 5) subjects will be randomized to GSK2982772 or
placebo in a 3:1 ratio. If required, subjects in the additional cohorts in Part A (Cohort 6)
and Part B (Cohort 7) will be randomized to GSK2982772 or placebo in a 1:1:1:1 and 3:1
ratio, respectively. The study duration, including screening and follow-up, is not expected
to exceed 105 days for any subject in the study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
| Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
| Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
| Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
| Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
| Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
| Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
| Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
| Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
| Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
| Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
| Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
| Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
| Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
| Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
| Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
| Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
| Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
| Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
| Completed |
NCT02874365 -
Intestinal Stem Cells Characterization
|
N/A |